openPR Logo
Press release

Global HIV Vaccine Market and Clinical Trial Outlook 2022 Report

05-07-2018 06:42 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global HIV Vaccine Market and Clinical Trial Outlook 2022 Report

“Global HIV Vaccine Market and Clinical Trial Outlook 2022” Report Highlights:

* Introduction to Human Immunodeficiency Virus (HIV) Vaccines
* HIV Vaccine Development Process
* Modified Approaches for HIV Vaccine Development
* HIV Drugs Taxonomy and Resistance
* Decisive Factors for Commercialization of HIV Vaccines
* Global HIV Vaccine Clinical Pipeline by Company, Indication and Phase
* Global HIV Vaccine Clinical Pipeline: 65 Vaccines

Download Report Sample Weblink:

https://www.kuickresearch.com/report--global-hiv-vaccine-market-and-clinical-trial-outlook-2022.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

Introduction to Human Immunodeficiency Virus (HIV) Vaccines
1.1 Overview
1.2 Antiquity of HIV Vaccine

Need for the Development of HIV Vaccine

Primer of HIV inside the Body
3.1 Inclusion of HIV Virus into the System
3.2 Interaction of HIV with Host
3.3 Eradication of HIV Virus

HIV Vaccine Development Process
4.1 Introduction
4.1.1 Classification of HIV Virus
4.1.2 Structure of HIV Virus
4.2 HIV Vaccine Construct Methodologies
4.2.1 Live Attenuated Vaccine
4.2.2 Synthetic Peptide Vaccines
4.2.3 Inactivated Vaccines
4.2.4 DNA Vaccine
4.2.5 Recombinant Vector Vaccine

Modified Approaches for HIV Vaccine Development
5.1 HIV Vaccine Expansion by Computer Aided Drug Design
5.2 Genetic Variety Attentions for Vaccine Design
5.3 Virus like Particles Approach for the HIV Vaccine Production
5.4 T-cell based Approach for HIV Vaccine

Prophylactic and Therapeutic HIV Vaccine
6.1 Prophylactic HIV Vaccine
6.1.1 Pre Exposure Prophylaxis
6.1.2 Post Exposure Prophylaxis (PEP)
6.2 Therapeutic HIV Vaccine

HIV Drugs Taxonomy and Resistance
7.1 Categorization of the Drugs
7.1.1 Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs)
7.1.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
7.1.3 Protease Inhibitors
7.1.4 Fusion Inhibitors
7.2 Contrivance of HIV Drug Resistance
7.2.1 Resistance to Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
7.2.2 Resistance to Non-Nucleoside Reverse Transcriptase Inhibitors
7.2.3 Resistance to Protease Inhibitors
7.2.4 Resistance to Fusion Inhibitors

Decisive Factors for Commercialization of HIV Vaccines
8.1 Efficacy
8.2 Controlled Transmission
8.3 Relapse
8.4 Economical
8.5 Manufacturing Scalability

Global HIV Vaccine Market Outlook
9.1 Overview
9.2 Current Market Scenario
9.3 Incidence and Prevalence
9.4 Funding Scenario for HIV Vaccine

Global HIV Vaccine Clinical Pipeline Overview

Global HIV Vaccine Market Dynamics
11.1 Favorable Market Parameters
11.2 Commercialization Challenges

Global HIV Vaccine Market Future Outlook


Global HIV Vaccine Clinical Pipeline by Company, Indication and Phase
13.1 Research
13.2 Preclinical
13.3 Clinical
13.4 Phase-I
13.5 Phase-I/II
13.6 Phase-II
13.7 Phase-III
13.8 Preregistration

Competitive Landscape
14.1 AlphaVax
14.2 Antigen Express
14.3 Argo Therapeutics
14.4 Bionor Pharmaceuticals
14.5 Celldex Therapeutics
14.6 FIT Biotech
14.7 Crucell Pharmaceutical
14.8 GeneCure
14.9 Genetic Immunity
14.10 GenVec
14.11 GeoVax Labs
14.12 Glaxo Smithkline
14.13 Immune Response BioPharma
14.14 Inovio Pharmaceuticals
14.15 Novartis
14.16 Oncolys Biopharma
14.17 PaxVax
14.18 Profectus Biosciences
14.19 Sanofi
14.20 TVAX Biomedical

Figure 1-1: Stages of HIV Infection
Figure 1-2: History of HIV
Figure 3-1: Modes of Transmission of HIV Virus into the System
Figure 3-2: Life Cycle of HIV Virus inside the Host Cell
Figure 4-1: Structure of HIV Virus
Figure 4-2: Approaches to Design an AIDS Vaccine
Figure 5-1: Modified Approaches for HIV Vaccine Development
Figure 7-1: Categories of Antiretroviral Drugs
Figure 7-2: Mechanism of Resistance to Nucleoside Reverse Transcriptase Inhibitors
Figure 7-3: Usage of Resistance to Non-Nucleoside Reverse Transcriptase Inhibitor
Figure 7-4: Resistance to Protease Inhibitors
Figure 7-5: Resistance to Fusion Inhibitors
Figure 8-1: Requirements for Successful Commercialization of HIV Vaccines
Figure 9-1: Global HIV/AIDS Therapeutics Market (US$ Billion), 2012-2022
Figure 9-2: Global - Truvada Sales (US$ Million), 2011-2015
Figure 9-3: Global andndash; Atripla Sales (US$ Million), 2011-2015
Figure 9-4: Global andndash; Prezista Sales (US$ Million), 2011-2015
Figure 9-5: Global andndash; Complera/Eviplera Sales (US$ Million), 2011-2015
Figure 9-6: Global andndash; Sustiva Sales (US$ Million), 2011-2015
Figure 9-7: Global andndash; Sustiva Sales (US$ Million), 2011-2015
Figure 9-8: Global andndash; Viread Sales (US$ Million), 2011-2015
Figure 9-9: Global andndash; Epzicom Sales (US$ Million), 2011-2015
Figure 9-10: Global andndash; Kaletra Sales (US$ Million), 2011-2015
Figure 9-11: Global andndash; Combivir Sales (US$ Million), 2011-2015
Figure 9-12: Global - HIV Incidence (Million), 2015
Figure 9-13: Global - People Living with HIV (Million), 2011-2015
Figure 9-14: Global andndash; New HIV Infections (Million), 2011-2015
Figure 9-15: Global andndash;HIV Deaths (Million), 2011-2015
Figure 9-16: Global andndash; People Living with HIV On Antiretroviral Therapy (Million), 2011-2015
Figure 9-17: US andndash; HIV Incidence (Million), 2015
Figure 9-18: Asia Pacific-HIV Incidence (Million), 2015
Figure 9-19: India - HIV Incidence (Million), 2015
Figure 9-20: Europe - HIV Incidence (Million), 2015
Figure 9-21: UK - HIV Incidence (Millions), 2015
Figure 9-22: South Africa - HIV Incidence (Million), 2015
Figure 9-23: Global - HIV prevention RandD Investments by Sector, 2015
Figure 9-24: US - Public Sector and Other Investments in HIV prevention RandD (%), 2011 to 2015
Figure 9-25: US - Public Sector Investments in HIV Prevention RandD by Technology (%), 2011 to 2015
Figure 9-26: Europe - Public Sector and Other Investments in HIV prevention RandD (%), 2011 to 2015
Figure 9-27: Europe - Public Sector Investments in HIV Prevention RandD by Technology (%), 2011 to 2015
Figure 9-28: Global - Investments in RandD Prevention by Top Philanthropic Funders (US$ Million)
Figure 9-29: Top Public Sector Investing in HIV Prevention RandD, 2012andndash;2015 (US$ Million)
Figure 9-30: HIV Vaccines by Country (%), 2014
Figure 9-31: Philanthropic Sector Spending on HIV Vaccines by Clinical Research Phase (%)
Figure 10-1: Global HIV - Vaccine Pipeline by Phase (%), 2016 to 2022
Figure 10-2: Global HIV - Vaccine Pipeline by Phase (Numbers), 2016 to 2022
Figure 10-3: Global HIV - Vaccine Drugs Discontinued and Suspended in Clinical Pipeline by Phase (%), 2016 to 2022
Figure 10-4: Global HIV - Vaccine Drugs Discontinued and Suspended in Clinical Pipeline by Phase (Numbers), 2016 to 2022
Figure 11-1: Driving Forces of HIV Vaccine Market
Figure 11-2: Challenges to the HIV Vaccine Development
Figure 14-1: AlphaVax Clinical Pipeline
Figure 14-2: Bionor Pharma Clinical Pipeline
Figure 14-3: Profectus BioSciences Clinical Pipeline
Figure 14-4: TVAX Biomedical Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global HIV Vaccine Market and Clinical Trial Outlook 2022 Report here

News-ID: 1040703 • Views: 233

More Releases from Kuick Resarch

Global Cell Therapy Market To Surpass US$ 35 Billion By 2026
Global cell therapy market is expected to surpass US$ 35 Billion by 2026 as per recent report “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” published by Kuick Research. Increasing investment, gaining research and development activities along with new technological advancement will drive the global cell therapy market. Download Report: https://www.kuickresearch.com/report-global-cell-therapy-market,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” Report Highlights: • Global Cell Therapy
Cell Therapy Market Size Growth Cell Therapy Clinical Trials Market Forecast 202 …
Cell therapies are still in the infancy stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that
Global Cell Therapy Market Size Analysis Clinical Trials Growth Forecast 2026
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
CAR T Cell Therapy Changing The Cancer Oncology Drug Market Landscape
" Global CAR T Cell Therapy Market & Clinical Trials Insight 2024" Report Highlights: • CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action • Sales Analysis of CAR - T Cell Therapy • CAR - T Cell Therapy Market Opportunity: US$ 700 Million • CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies • CAR-T Cell Therapies in Highest Phase: Preclinical • Marketed CAR-T Cell Therapies: 2 ( Yescarta & Kymriah) • Global Market Scenario of

All 5 Releases


More Releases for HIV

Global HIV Market to 2024
The HIV market was valued at $16bn in 2015 and is forecast to expand at a CAGR of 3.7% between 2015 and 2024, culminating in 2024 global sales of $23bn.The expected arrival of new classes of therapies could result in a paradigm shift in the treatment of HIV treatment. Globally, around 35 million people are infected with HIV. Approximately 3 million people in the U.S and 2.5 million in top 5
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Global HIV Infection Pipeline Analysis
The discovery of HIV virus, which causes AIDS, dates back to more than 30 years. Currently, there are more than 30 drugs in the market which have been approved by the FDA for the treatment of HIV infection. Consequent to the introduction of retrovirals in 1996, HIV is not considered to be a death sentence anymore. The advancements in this field have led to new drugs being produced which have
Global HIV Therapeutics Market
The HIV Therapeutics Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. The human immunodeficiency virus (HIV) refers to a type of retrovirus that causes acquired immunodeficiency syndrome (AIDS). HIV attacks some immune cells and causes weakness of immune system resulting in loss
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus. Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral